Form 4: Intra-Cellular Therapies Director Rory B. Riggs Acquires Stock Options and Restricted Stock Units

Director Rory B. Riggs acquired stock options and restricted stock units in Intra-Cellular Therapies, Inc. on June 14, 2024.

Summary

• On June 14, 2024, Rory B. Riggs, a director of Intra-Cellular Therapies, Inc., acquired 4,322 stock options with an exercise price of $67.77, expiring on June 13, 2034.
• Riggs also acquired 2,951 restricted stock units (RSUs) that vest on June 14, 2025.
• Each RSU represents a contingent right to receive one share of common stock.
• Following these transactions, Riggs directly owns 4,322 stock options and 2,951 restricted stock units.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a routine disclosure of insider transactions. The acquisition of stock options and RSUs could be seen as a slightly positive sign, but it's not definitive.

Positives

• The acquisition of stock options and restricted stock units by a director may signal confidence in the company's future performance.

Industry Context

This is a standard Form 4 filing, reflecting changes in beneficial ownership by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.

Comparison to Industry Standards

• Insider transactions are a common occurrence in publicly traded companies.
• The size and nature of the transaction (stock options and RSUs) are typical forms of executive compensation.
• Comparing the vesting schedules and exercise prices to those of peer companies (e.g., other biotech firms of similar size and stage) would provide further context.

Stakeholder Impact

• The transactions may have a minor positive impact on shareholder sentiment if viewed as a sign of confidence by the director.

Key Dates